---
schema_version: "secwatch.filing_event.v1"
accession: "0001534120-25-000005"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2025-09-22T23:59:59+00:00"
generated_at: "2026-05-17T05:58:09.244397+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics appoints Kevin Lind to Board effective Oct 1; Dr. Almenoff resigns

## Summary
- Kevin Lind appointed to Board effective Oct 1, 2025; will serve on Audit Committee and receive option for 40,200 shares vesting over 3 years.
- Lind previously led Longboard Pharmaceuticals to $2.6B acquisition by Lundbeck in 2024; was EVP/CFO at Arena Pharmaceuticals.
- June Almenoff resigns as director effective Oct 1; her equity awards modified to vest fully and options extended to Sept 30, 2026.
- Company advancing Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa; topline data expected mid-2026.

## SEC filing metadata
- accession: 0001534120-25-000005
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2025-09-22T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000153412025000005/0001534120-25-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000153412025000005/avtx-20250916.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534120-25-000005
- JSON: https://secwatch.observer/filing/0001534120-25-000005.json
- Plain text: https://secwatch.observer/filing/0001534120-25-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.